Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
Atypical teratoid rhabdoid tumors (ATRT) are very rare, aggressive tumors of the central nervous system, occurring mostly in the cerebellum or the brain stem and are more commonly diagnosed in young children. The signs and symptoms of atypical teratoid rhabdoid tumor varies with patient to patient and depend on the child's age as well as tumor location. A diagnosis of typical Teratoid Rhabdoid Tumors (ATRT) is based upon a thorough clinical evaluation, and a variety of specialized tests. ATRT is most commonly diagnosed from imaging studies like Magnetic resonance imaging (MRI), Computerized tomography scan, Lumbar puncture, Ultrasound, and biopsy. Treatment of ATRT mainly includes surgery, chemotherapy or radiation therapy. Combinatorial treatment of surgical resection, chemotherapy, and radiation therapy is widely used. Multiple clinical trials testing molecularly targeted therapies are underway.
'Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape is provided which includes the disease overview and Atypical Teratoid Rhabdoid Tumors (ATRT) treatment guidelines. The assessment part of the report embraces, in depth Atypical Teratoid Rhabdoid Tumors (ATRT) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atypical Teratoid Rhabdoid Tumors (ATRT) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Atypical Teratoid Rhabdoid Tumors (ATRT) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atypical Teratoid Rhabdoid Tumors (ATRT) Emerging Drugs
Further product details are provided in the repor
Atypical Teratoid Rhabdoid Tumors (ATRT): Therapeutic Assessment
This segment of the report provides insights about the different Atypical Teratoid Rhabdoid Tumors (ATRT) drugs segregated based on following parameters that define the scope of the report, such as:
Atypical Teratoid Rhabdoid Tumors (ATRT): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Teratoid Rhabdoid Tumors (ATRT) drugs.
Atypical Teratoid Rhabdoid Tumors (ATRT) Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
Atypical teratoid rhabdoid tumors (ATRT) are very rare, aggressive tumors of the central nervous system, occurring mostly in the cerebellum or the brain stem and are more commonly diagnosed in young children. The signs and symptoms of atypical teratoid rhabdoid tumor varies with patient to patient and depend on the child's age as well as tumor location. A diagnosis of typical Teratoid Rhabdoid Tumors (ATRT) is based upon a thorough clinical evaluation, and a variety of specialized tests. ATRT is most commonly diagnosed from imaging studies like Magnetic resonance imaging (MRI), Computerized tomography scan, Lumbar puncture, Ultrasound, and biopsy. Treatment of ATRT mainly includes surgery, chemotherapy or radiation therapy. Combinatorial treatment of surgical resection, chemotherapy, and radiation therapy is widely used. Multiple clinical trials testing molecularly targeted therapies are underway.
'Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape is provided which includes the disease overview and Atypical Teratoid Rhabdoid Tumors (ATRT) treatment guidelines. The assessment part of the report embraces, in depth Atypical Teratoid Rhabdoid Tumors (ATRT) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atypical Teratoid Rhabdoid Tumors (ATRT) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Teratoid Rhabdoid Tumors (ATRT) R&D. The therapies under development are focused on novel approaches to treat/improve Atypical Teratoid Rhabdoid Tumors (ATRT).
This segment of the Atypical Teratoid Rhabdoid Tumors (ATRT) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atypical Teratoid Rhabdoid Tumors (ATRT) Emerging Drugs
- Tazemetostat: Epizyme
- ONC206: Chimerix
Further product details are provided in the repor
Atypical Teratoid Rhabdoid Tumors (ATRT): Therapeutic Assessment
This segment of the report provides insights about the different Atypical Teratoid Rhabdoid Tumors (ATRT) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Atypical Teratoid Rhabdoid Tumors (ATRT)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Atypical Teratoid Rhabdoid Tumors (ATRT): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Teratoid Rhabdoid Tumors (ATRT) drugs.
Atypical Teratoid Rhabdoid Tumors (ATRT) Report Insights
- Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Atypical Teratoid Rhabdoid Tumors (ATRT) drugs?
- How many Atypical Teratoid Rhabdoid Tumors (ATRT) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atypical Teratoid Rhabdoid Tumors (ATRT)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atypical Teratoid Rhabdoid Tumors (ATRT) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Takeda Oncology
- Chimerix
- Epizyme
- Pfizer
- Vyriad
- DNAtrix
- Lantern Pharma
- Alisertib
- ONC206
- Tazemetostat
- Palbociclib
- MV-NIS
- DNX-2401
- LP-184
Introduction
Executive Summary
Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Atypical Teratoid Rhabdoid Tumors (ATRT) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atypical Teratoid Rhabdoid Tumors (ATRT) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Atypical Teratoid Rhabdoid Tumors (ATRT) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tazemetostat: Epizyme
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ONC206: Chimerix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
DNX-2401: DNAtrix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Products
Atypical Teratoid Rhabdoid Tumors (ATRT)- Unmet Needs
Atypical Teratoid Rhabdoid Tumors (ATRT)- Market Drivers and Barriers
Atypical Teratoid Rhabdoid Tumors (ATRT)- Future Perspectives and Conclusion
Atypical Teratoid Rhabdoid Tumors (ATRT) Analyst Views
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
Appendix
Executive Summary
Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Atypical Teratoid Rhabdoid Tumors (ATRT) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atypical Teratoid Rhabdoid Tumors (ATRT) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Atypical Teratoid Rhabdoid Tumors (ATRT) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tazemetostat: Epizyme
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ONC206: Chimerix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
DNX-2401: DNAtrix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Products
Atypical Teratoid Rhabdoid Tumors (ATRT)- Unmet Needs
Atypical Teratoid Rhabdoid Tumors (ATRT)- Market Drivers and Barriers
Atypical Teratoid Rhabdoid Tumors (ATRT)- Future Perspectives and Conclusion
Atypical Teratoid Rhabdoid Tumors (ATRT) Analyst Views
Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
